Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 7 February

Sophia Mavridis
February 7, 2022

Weekly Wrap 4 February

Sophia Mavridis
February 4, 2022

Morning Bell 3 February

Paulina Peters
February 3, 2022

Morning Bell February 2

Sophia Mavridis
February 2, 2022

Morning Bell 1 February

Paulina Peters
February 1, 2022

Morning Bell 31 January

Sophia Mavridis
January 31, 2022

Weekly Wrap 28 January

Sophia Mavridis
January 28, 2022

Morning Bell 27 January

Sophia Mavridis
January 27, 2022

Morning Bell 25 January

Paulina Peters
January 25, 2022

Morning Bell 24 January

Paulina Peters
January 24, 2022

Weekly Wrap 21 January

Sophia Mavridis
January 21, 2022

Morning Bell 20 January

Paulina Peters
January 20, 2022